On February 15 this year. new Summary of Product Characteristics for COMIRNATY has been approved.

Comirnates, 30 micrograms/dose, concentrate for dispersion for injection (with purple cap) and
Comirnates, 10 micrograms/dose, concentrate for dispersion for injection (with orange cap).

The changes concern the impact of Pfizer/BionTech mRNA vaccines against SARS-CoV-2 on pregnancy and lactation.

Pregnancy

Observational data from a large number of women vaccinated with Comirnaty during the second and third trimesters of pregnancy did not show an increase in the incidence of pregnancy disorder. Data on the course of pregnancy after vaccination during the first trimester are currently limited, but there is no evidence of an increased risk of miscarriage. Animal studies have shown no evidence of direct or indirect harmful effects on pregnancy, embryofoetal development, parturition or postnatal development (see section 5.3). Comirnaty can be used during pregnancy.

Breastfeeding

No effects on the breastfed newborns/infants are anticipated as systemic exposure to Comirnaty is minimal in breastfeeding women. Observational data from breastfeeding women following vaccination did not reveal a risk of adverse reactions in the breastfed newborns/infants. Comirnaty can be used during breast-feeding.

I hope that this information from observational research will break through the pseudoscientific gibberish of followers of acquiring immunity with mixtures of urine from the old goat and the dead goat toads .